100 related articles for article (PubMed ID: 8961354)
1. Engineering the C-region of human insulin-like growth factor-1: implications for receptor binding.
Gill R; Wallach B; Verma C; Ursø B; De Wolf E; Grötzinger J; Murray-Rust J; Pitts J; Wollmer A; De Meyts P; Wood S
Protein Eng; 1996 Nov; 9(11):1011-9. PubMed ID: 8961354
[TBL] [Abstract][Full Text] [Related]
2. Structural changes in insulin-like growth factor (IGF) I mutant proteins affecting binding kinetic rates to IGF binding protein 1 and IGF-I receptor.
Jansson M; Uhlen M; Nilsson B
Biochemistry; 1997 Apr; 36(14):4108-17. PubMed ID: 9100004
[TBL] [Abstract][Full Text] [Related]
3. Structure-function studies of an IGF-I analogue that can be chemically cleaved to a two-chain mini-IGF-I.
Geddes S; Holst P; Grotzinger J; Gill R; Nugent P; De Meyts P; Wollmer A; Wood S; Pitts J
Protein Eng; 2001 Jan; 14(1):61-5. PubMed ID: 11287679
[TBL] [Abstract][Full Text] [Related]
4. Mutations at positions 11 and 60 of insulin-like growth factor 1 reveal differences between its interactions with the type I insulin-like-growth-factor receptor and the insulin receptor.
Hodgson DR; May FE; Westley BR
Eur J Biochem; 1995 Oct; 233(1):299-309. PubMed ID: 7588759
[TBL] [Abstract][Full Text] [Related]
5. The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor.
Bayne ML; Applebaum J; Underwood D; Chicchi GG; Green BG; Hayes NS; Cascieri MA
J Biol Chem; 1989 Jul; 264(19):11004-8. PubMed ID: 2472386
[TBL] [Abstract][Full Text] [Related]
6. Positively charged side chains in the insulin-like growth factor-1 C- and D-regions determine receptor binding specificity.
Zhang W; Gustafson TA; Rutter WJ; Johnson JD
J Biol Chem; 1994 Apr; 269(14):10609-13. PubMed ID: 8144650
[TBL] [Abstract][Full Text] [Related]
7. The different folding behavior of insulin and insulin-like growth factor 1 is mainly controlled by their B-chain/domain.
Guo ZY; Shen L; Feng YM
Biochemistry; 2002 Feb; 41(5):1556-67. PubMed ID: 11814349
[TBL] [Abstract][Full Text] [Related]
8. Refolding of amphioxus insulin-like peptide: implications of a bifurcating evolution of the different folding behavior of insulin and insulin-like growth factor 1.
Wang S; Guo ZY; Shen L; Zhang YJ; Feng YM
Biochemistry; 2003 Aug; 42(32):9687-93. PubMed ID: 12911310
[TBL] [Abstract][Full Text] [Related]
9. Modelling of the disulphide-swapped isomer of human insulin-like growth factor-1: implications for receptor binding.
Gill R; Verma C; Wallach B; Ursø B; Pitts J; Wollmer A; De Meyts P; Wood S
Protein Eng; 1999 Apr; 12(4):297-303. PubMed ID: 10325399
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the B-domain of insulin-like growth factor-I influence the oxidative folding to yield products with modified biological properties.
Milner SJ; Francis GL; Wallace JC; Magee BA; Ballard FJ
Biochem J; 1995 Jun; 308 ( Pt 3)(Pt 3):865-71. PubMed ID: 8948444
[TBL] [Abstract][Full Text] [Related]
11. Characterization of ligand binding of a soluble human insulin-like growth factor I receptor variant suggests a ligand-induced conformational change.
Jansson M; Hallén D; Koho H; Andersson G; Berghard L; Heidrich J; Nyberg E; Uhlén M; Kördel J; Nilsson B
J Biol Chem; 1997 Mar; 272(13):8189-97. PubMed ID: 9079636
[TBL] [Abstract][Full Text] [Related]
12. Development of an optimized refolding process for recombinant Ala-Glu-IGF-1.
Hejnaes KR; Bayne S; Nørskov L; Sørensen HH; Thomsen J; Schäffer L; Wollmer A; Skriver L
Protein Eng; 1992 Dec; 5(8):797-806. PubMed ID: 1287661
[TBL] [Abstract][Full Text] [Related]
13. Disulfide exchange folding of disulfide mutants of insulin-like growth factor I in vitro.
Hober S; Uhlén M; Nilsson B
Biochemistry; 1997 Apr; 36(15):4616-22. PubMed ID: 9109671
[TBL] [Abstract][Full Text] [Related]
14. Binding protein-3-selective insulin-like growth factor I variants: engineering, biodistributions, and clearance.
Dubaquié Y; Mortensen DL; Intintoli A; Hogue DA; Nakamura G; Rancatore P; Lester P; Sadick MD; Filvaroff E; Fielder PJ; Lowman HB
Endocrinology; 2001 Jan; 142(1):165-73. PubMed ID: 11145579
[TBL] [Abstract][Full Text] [Related]
15. The different energetic state of the intra A-chain/domain disulfide of insulin and insulin-like growth factor 1 is mainly controlled by their B-chain/domain.
Guo ZY; Shen L; Feng YM
Biochemistry; 2002 Aug; 41(34):10585-92. PubMed ID: 12186542
[TBL] [Abstract][Full Text] [Related]
16. [The structural organization of binding determinants in insulin-like growth factor-I (IGF-I) molecule].
Kolychev AP
Zh Evol Biokhim Fiziol; 2010; 46(1):74-94. PubMed ID: 20297673
[TBL] [Abstract][Full Text] [Related]
17. Sequences of B-chain/domain 1-10/1-9 of insulin and insulin-like growth factor 1 determine their different folding behavior.
Chen Y; You Y; Jin R; Guo ZY; Feng YM
Biochemistry; 2004 Jul; 43(28):9225-33. PubMed ID: 15248780
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs.
Oh Y; Müller HL; Lee DY; Fielder PJ; Rosenfeld RG
Endocrinology; 1993 Mar; 132(3):1337-44. PubMed ID: 7679979
[TBL] [Abstract][Full Text] [Related]
19. Involvement of phenylalanine 23 in the binding of IGF-1 to the insulin and type I IGF receptor.
Hodgson DR; May FE; Westley BR
Regul Pept; 1996 Oct; 66(3):191-6. PubMed ID: 8916274
[TBL] [Abstract][Full Text] [Related]
20. Binding affinities of insulin-like growth factor-I (IGF-I) fusion proteins to IGF binding protein 1 and IGF-I receptor are not correlated with mitogenic activity.
Jansson M; Dixelius J; Uhlen M; Nilsson BO
FEBS Lett; 1997 Oct; 416(3):259-64. PubMed ID: 9373165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
